DiaMedica Therapeutics Inc DMAC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results
-
DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences
-
DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
-
DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026
Trading Information
- Previous Close Price
- $8.04
- Day Range
- $7.53–8.10
- 52-Week Range
- $5.25–10.42
- Bid/Ask
- $7.60 / $8.50
- Shares Outstanding
- 53.93M
- Market Cap
- $408.22M
- Volume/Avg
- 260,778 / 184,258
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 35
- Website
- https://www.diamedica.com
Valuation
|
Metric
|
DMAC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 10.65 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
DMAC
|
|---|---|
Quick Ratio | 6.63 |
Current Ratio | 6.72 |
Interest Coverage | — |
Quick Ratio
DMAC
Profitability
|
Metric
|
DMAC
|
|---|---|
Return on Assets (Normalized) | −68.59% |
Return on Equity (Normalized) | −77.14% |
Return on Invested Capital (Normalized) | −76.72% |
Return on Assets
DMAC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!?$Tlp@ | LOCK|ZRwYH | $127B | |||
| Moderna Inc
MRNA
| LOCK|>fRfn^ | LOCK|PDT | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|HW#<!<N | LOCK|WbKd? | $81B | |||
| argenx SE ADR
ARGX
| LOCK|$z#><vm | LOCK|qC | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|yT<%gS | LOCK|gP | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|w$rb#>S | LOCK|??@M! | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|w&y%#w>P | LOCK|!GmGJ | $27B | |||
| Incyte Corp
INCY
| LOCK|fX<^Jck | LOCK|?Rx | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|W%@?TXp | LOCK|RQ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|xx!zTkc | LOCK|#N | $14B |
United States